Fluciclovine
Urogenital Neoplasms
VA Greater Los Angeles Healthcare SystemradiopharmaceuticalPhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 89/ 100
Competitive context
20 Active assets in the Urogenital Neoplasms cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
PREDNISONE TABLETS Eli Lilly and Company | Phase 3 | BB |
Epirubicin Sheba Medical Center | Phase 2 | B |
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE Eli Lilly and Company | Phase 3 | B |
Abemaciclib Eli Lilly and Company | Phase 3 | B |
FULVESTRANT Atavistik Bio, Inc | Phase 2 | B |
View all 34 →
Same molecule, other indications
Fluciclovine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →